F-1/A: PainReform Ltd. Announces Proposed Securities Offering

PainReform Ltd. is offering up to 4,132,231 ordinary shares, pre-funded warrants, and common warrants in a best-efforts offering.

Summary

• PainReform Ltd. is offering up to 4,132,231 ordinary shares on a best-efforts basis at an assumed price of $1.21 per share.
• The company is also offering pre-funded warrants to certain purchasers who would otherwise exceed beneficial ownership limits.
• Each ordinary share or pre-funded warrant is offered with one common warrant to purchase one ordinary share at an exercise price of $1.21, expiring five years from the issuance date.
• The offering is expected to terminate on April 30, 2024, and H.C. Wainwright & Co., LLC is acting as the exclusive placement agent.
• The company intends to use the net proceeds from this offering to advance its clinical studies and for general corporate purposes.
• The company's ordinary shares are listed on the Nasdaq under the symbol PRFX.

Sentiment

Score: 5

Explanation: The document presents a factual overview of the proposed securities offering. While the offering itself can be seen as a positive step for the company's financial health, the risks associated with the offering and the company's financial situation temper the overall sentiment.

Positives

• The offering will provide capital to advance clinical studies.
• The company has engaged H.C. Wainwright & Co., LLC, a reputable placement agent.
• The company's ordinary shares are already listed on the Nasdaq Capital Market.

Negatives

• The offering is on a best-efforts basis, so there is no guarantee that all securities will be sold.
• The company may receive significantly less in net proceeds than anticipated.
• There is no established trading market for the pre-funded warrants or the common warrants.
• The company has broad discretion over the use of the net proceeds.

Risks

• The best-efforts structure of the offering may have an adverse effect on the company's business plan.
• The company may have insufficient capital to implement its business plan.
• The company will need additional capital in the future, and raising additional capital may cause dilution to existing shareholders.
• Conditions in the Middle East and in Israel may harm the company's operations.
• The company is a PFIC for the 2023 taxable year and expects to be a PFIC for the 2024 taxable year.

Future Outlook

The company currently intends to use the net proceeds of this offering to advance its clinical studies and for general corporate purposes. Pending such uses, the company intends to invest the net proceeds in bank deposits.

Industry Context

The company operates in the specialty pharmaceutical industry, focusing on the reformulation of established therapeutics for post-surgical pain relief.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The offering may provide the company with the financial resources to advance its clinical studies, potentially benefiting patients.
• The company's employees may benefit from the continued operation and growth of the company.

Next Steps

• The company will offer and sell the securities through the Placement Agent.
• The company will deliver the securities on or about a specified date in 2024, subject to customary closing conditions.
• The company will file a prospectus with the SEC pursuant to Rule 424.
• The company will apply to list the Shares and Warrant Shares on a Trading Market.

Key Dates

Keywords

ordinary shares, pre-funded warrants, common warrants, offering, PainReform, clinical studies, placement agent, H.C. Wainwright, securities, PRFX